Eventide Asset Management’s Alto Neuroscience ANRO Stock Holding History

Eventide Asset Management’s Portfolio ANRO Stock Details ANRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$10.9M	Buy	+425,000	New	+$12.8M	0.15%	148

Other funds holding ANRO

Alpha Wave Global New York $4.27B AUM 12.79% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Spruce Street Capital New York $629M AUM 210.46% 1-Year Est. Return

Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return

Eventide Asset Management's ANRO Position: Q3 2026 in Review

Eventide Asset Management opened a new position in Alto Neuroscience (ANRO) in Q3 2026: 425,000 shares worth $10.9M. The stake represents 0.15% of the portfolio and ranks #148 among its holdings.

87 funds tracked by Wall St. Rank hold ANRO as of Q3 2026.

Eventide Asset Management held 425,000 shares of Alto Neuroscience worth $10.9M as of Q3 2026.
Alto Neuroscience was a new Eventide Asset Management position in Q3 2026.
Alto Neuroscience made up 0.15% of Eventide Asset Management's portfolio in Q3 2026, its #148 holding.
87 funds tracked by Wall St. Rank held Alto Neuroscience as of Q3 2026.

Based on Eventide Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.